NTBL (Notable Labs, Ltd.) Pangali Forward P/E
The forward P/E ratio of Notable Labs, Ltd. (NTBL) correlates with the implementation of ESG platforms for oncology therapy optimization, while the value of 0.00 expresses the metric level. Business development relies on external IT outsourcing for the creation of AI algorithms and the execution of clinical tests. The stability of operational processes is supplemented by a streamlined express delivery system for biomaterials, which eliminates laboratory delays.
Ringkesan rincian data analitis notablelabs.com (NTBL)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Notable Labs, Ltd.|NTBL - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Notable Labs Inc.|NTBL - Utang agregat perusahaan|Rasio utang marang kapitalisasi buku Notable Labs Ltd|NTBL - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Notable Labs|Rasio cepet notablelabs.com
- rincian asil keuangan lan kelipatan valuasi:
NTBL - Bathi resik|Proyeksi bathi mangsa ngarep Notable Labs, Ltd.|NTBL - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Notable Labs, Ltd.|NTBL - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Notable Labs Ltd|NTBL - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Notable Labs|NTBL - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan notablelabs.com|NTBL - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Notable Labs, Ltd.
- indikator volume dodolan lan pendapatan:
Ringkesan analitik perusahaan:NTBL notablelabs.com
The forward P/E ratio relates the current market value of Notable Labs, Ltd. (NTBL) to expected net income, measuring the market's willingness to pay a premium for future earnings. For the PPMP IT ecosystem, where commercial success depends on FDA verdicts and clinical trial results, the forward P/E valuation of Notable Labs, Ltd. (NTBL) reflects speculative demand for AI biomaterial analysis patents in the absence of commercialized products.
Pesaing Notable Labs, Ltd. (NTBL)
Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Bio (BCAX) - Rega marang bathi mangsa ngarep|Personalis Corp - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Systems, Inc. DCTH|Prakiraan rega marang bathi YMAB (Y-mAbs Corp)|Pangali Forward P/E Aura Bio (AURA)|Pangali Forward P/E CADL (Candel Therapeutics Inc.)|ARAY - Prakiraan rega marang bathi|SLS - Rega marang bathi mangsa ngarep|Actuate Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|CTOR: Pangali Forward P/E|TuHURA (HURA) - Pangali Forward P/E|TARA (Protara Therapeutics Inc) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|TCRX (TScan) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT - Prakiraan rega marang bathi|CEL-SCI - Pangali Forward P/E|OSTX - Pangali Forward P/E|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|ARTV - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ANL|Rega marang bathi mangsa ngarep VERU|Pangali Forward P/E TPST|XLO: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E RENB (Renovaro Inc.)|Mural Bio (MURA) - Rasio prakiraan rega marang bathi|Kairos Pharma Ltd - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake OKUR|CytoMed Therapeutics Limited (GDTC) - Rega marang bathi mangsa ngarep|CRIS - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi APLM|Tharimmune (THAR) - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ADVB (Advanced Biomed Inc.)|Genprex - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Prakiraan rega marang bathi|Xenetic Bio - Pangali Forward P/E|SLRX - Pangali Forward P/E|PPBT: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep AONC|BGNE (BeiGene Ltd) - Pangali Forward P/E|CKPT (Checkpoint Therapeutics, Inc) - Rasio kapitalisasi marang bathi mangsa ngarep|Pangali Forward P/E ELEV|Prakiraan rega marang bathi iCAD Corp ICAD|Rega marang bathi mangsa ngarep ikenaoncology.com IKNA|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E
